Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxaliplatin added to neoadjuvant chemotherapy for locally advanced breast cancer
IRCT20181224042104N1Phase 2Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Apr 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin in breast cancer, sponsored by Shiraz University of Medical Sciences. Primary endpoints: Pathologic response and Drug toxicity. Started Apr 2019; status: completed.
02
Drugs
oxaliplatin
03
Conditions
breast cancer
Beyond the preview
Go deeper on IRCT20181224042104N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20181224042104N1.